Armata SVP granted 109,885 stock options

Armata Pharmaceuticals, Inc. reported that SVP, Finance, and Principal Financial Officer David Duane House received a grant of stock options to acquire 109,885 shares of Common Stock at an exercise price of $11.61 per share.

Rhea-AI Filing Summary

Armata Pharmaceuticals, Inc. reported that SVP, Finance, and Principal Financial Officer David Duane House received a grant of stock options to acquire 109,885 shares of Common Stock at an exercise price of $11.61 per share. These options were granted at no upfront cost and expire on March 9, 2036. According to the vesting terms, 25% of the options will vest on March 9 of each of 2027, 2028, 2029, and 2030, subject to his continuous service through each vesting date. Following this grant, he holds 109,885 stock options directly.

Insights

Executive compensation analyst

Routine multi‑year stock option grant to Armata’s finance chief.

The transaction reflects a compensation-related grant of 109,885 stock options to Armata Pharmaceuticals SVP, Finance, and PFO David Duane House at an exercise price of $11.61 per share, expiring in 2036. There is no open-market buying or selling.

The options vest in four equal annual installments on March 9 of 2027, 2028, 2029, and 2030, conditioned on continuous service. This structure is typical for long-term incentives, tying realized value to both tenure and future share performance.

Because this is a standard grant/award acquisition with no immediate cash transaction and no sale of existing shares, its impact is primarily in aligning the finance leader’s incentives with shareholder outcomes over the vesting and option life.

Insider Trade Summary

Grant/Award: 109,885 shares

Grant/Award 1 txn

Insider House David Duane

Role SVP, Finance, and PFO

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	109,885	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to Buy) — 109,885 contracts (Direct)

Footnotes (1)

1. F1. Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Armata Pharmaceuticals (ARMP) disclose in this Form 4?

Armata Pharmaceuticals reported a stock option grant to its SVP, Finance, and PFO, David Duane House. He received options for 109,885 shares of Common Stock at an exercise price of $11.61 per share, expiring in 2036, as part of his compensation.

How many Armata Pharmaceuticals (ARMP) options were granted to David Duane House?

David Duane House was granted stock options covering 109,885 shares of Armata Pharmaceuticals Common Stock. The options are a single award, and following this grant he holds 109,885 stock options directly, all tied to an exercise price of $11.61 per share.

What is the exercise price and expiration date of the ARMP options granted?

The granted stock options have an exercise price of $11.61 per share and expire on March 9, 2036. This means House can choose to exercise the options at that price any time before expiration, subject to vesting and plan conditions.

What is the vesting schedule for David Duane House’s Armata Pharmaceuticals options?

The options vest in four equal annual tranches. Twenty-five percent vests on March 9 of each of 2027, 2028, 2029, and 2030, in each case conditioned on House’s continuous service with Armata Pharmaceuticals through the applicable vesting date.

Is this Armata Pharmaceuticals (ARMP) Form 4 a stock purchase or a compensation grant?

This Form 4 reflects a compensation-related grant, not an open-market stock purchase. The transaction is coded as an “A” grant/award of stock options, giving House the right to buy 109,885 shares at $11.61 per share if and when the options vest.

Did David Duane House sell any Armata Pharmaceuticals (ARMP) shares in this filing?

No, the filing shows no stock sales. It reports only a grant of stock options to acquire 109,885 shares in the future, subject to vesting. There are no open-market sale transactions or tax-withholding dispositions disclosed in this Form 4 entry.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 09:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

House David Duane

(Last) (First) (Middle)

5005 MCCONNELL AVENUE

(Street)

LOS ANGELES CA 90066

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Armata Pharmaceuticals, Inc. [ ARMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance, and PFO

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$11.61	03/09/2026		A		109,885		(1)	03/09/2036	Common Stock	109,885	$0.00	109,885	D

Explanation of Responses:

1. Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date.

	/s/ David Duane House	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.